Golodirsen for Duchenne muscular dystrophy.

Area of Science:

• Genetics
• Molecular Biology
• Pharmacology

Background:

• Duchenne muscular dystrophy (DMD) is a severe X-linked genetic disorder caused by mutations in the DMD gene, leading to dystrophin deficiency.
• Most DMD mutations result in out-of-frame exon deletions, preventing functional dystrophin production.
• Antisense oligonucleotides (AONs) offer a therapeutic strategy by inducing exon skipping to restore the dystrophin reading frame.

Purpose of the Study:

• To review the pharmacology, efficacy, and safety of golodirsen, an AON-based therapy for DMD.
• To discuss the therapeutic potential of golodirsen in patients amenable to exon 53 skipping.
• To address post-approval controversies surrounding golodirsen.

Main Methods:

• Review of pharmacological data for golodirsen.
• Analysis of clinical trial data on golodirsen's efficacy and safety.
• Discussion of regulatory and clinical controversies related to golodirsen.

Main Results:

• Golodirsen is a phosphorodiamidate morpholino oligomer (PMO) designed to skip exon 53 in the DMD gene transcript.
• This exon skipping aims to restore the reading frame and enable the production of partially functional dystrophin.
• Golodirsen is indicated for a subset of DMD patients (approx. 8%) with specific mutations amenable to exon 53 skipping.

Conclusions:

• Golodirsen represents a targeted therapeutic approach for specific Duchenne muscular dystrophy mutations.
• The drug's efficacy and safety profile require ongoing evaluation, alongside consideration of associated controversies.
• Further research and long-term monitoring are essential for understanding golodirsen's role in DMD management.